Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
39S ribosomal protein L33, mitochondrial (MRPL33) is a nuclear-encoded structural protein forming part of the large (39S) subunit of the mitochondrial ribosome in humans. It is responsible for aiding mitochondrial protein synthesis, a critical process for the function of mitochondria. Mitochondrial ribosomal proteins like MRPL33 differ significantly in sequence and biochemical properties from their prokaryotic counterparts, making sequence-based identification challenging. Dysfunction of MRPL33 has been associated with mitochondrial diseases such as Leigh Disease and may have a role in mitochondrial-related tumor progression[1][2][7][8][9]. MRPL33 is not a classical drug target such as a receptor, enzyme, or transporter, but a ribosomal structural protein. There is no evidence it is directly targeted by approved drugs or used as a biomarker in clinical practice. Alternative splice variants exist; MRPL33's main function is as part of the mitochondrial translation machinery[1][2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 39S ribosomal protein L33, mitochondrial (MRPL33).